Evidence map›Paper›PMID 41760994›Full record

ArticleDiscover oncology2026

A bibliometric analysis of advances in N6‑methyladenosine research in colorectal cancer.

Lejin Zhao, Ying Sun, Junchao Li, Wenlong Yang, Zaipan Wang, Benguo Yu, Le Du

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lejin Zhao *Key Laboratory of Tropical Translational Medicine of Ministry of Education, School of Basic Medical Sciences, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, 571199, China.
Ying Sun *Key Laboratory of Tropical Translational Medicine of Ministry of Education, School of Basic Medical Sciences, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, 571199, China.
Junchao LiKey Laboratory of Tropical Translational Medicine of Ministry of Education, School of Basic Medical Sciences, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, 571199, China.
Wenlong YangKey Laboratory of Tropical Translational Medicine of Ministry of Education, School of Basic Medical Sciences, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, 571199, China.
Zaipan WangKey Laboratory of Tropical Translational Medicine of Ministry of Education, School of Basic Medical Sciences, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, 571199, China.
Benguo YuSchool of Intelligent Medicine and Technology, Big Data Research Center, Hainan Medical University, Haikou, 571199, Hainan, China. yubg@muhn.edu.cn.
Le DuKey Laboratory of Tropical Translational Medicine of Ministry of Education, School of Basic Medical Sciences, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, 571199, China. cgdule@muhn.edu.cn.

Funding

Hainan Medical University XSTS2025019Hainan Medical University XSTS2025194
6 · The paper itself

Abstract

Colorectal cancer (CRC) is a leading cause of cancer-related mortality globally. Epigenetic regulation, especially N6-methyladenosine (m6A) RNA modification, plays a critical role in CRC development. Although molecular studies have linked m6A to CRC progression, comprehensive bibliometric assessments are scarce. We analyzed 230 publications from the Web of Science (2014–2024) using CiteSpace and VOSviewer. Highly cited studies emphasize regulators such as METTL3 and IGF2BP2 in stemness and metabolic reprogramming. A emerging trend is the integration of m6A with tumor immunotherapy, indicating a shift from basic research toward clinical translation. This evolution highlights new therapeutic opportunities in CRC.

Indexed as

AngiogenesisBibliometric analysisColorectal cancerlmmunotherapyN6-methyladenosineOncologyTranslationVisualization

Identifiers

PMID41760994
PMCPMC13049124

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.